ID   94-10
AC   CVCL_8608
SY   TCC 94-10
DR   Cosmic; 2050431
DR   Cosmic; 2057436
DR   Cosmic; 2212691
DR   Cosmic; 2444254
DR   Wikidata; Q54605778
RX   PubMed=9436977;
RX   PubMed=10919661;
RX   PubMed=24035680;
RX   PubMed=24367658;
RX   PubMed=29732388;
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   74Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 15
//
RX   PubMed=9436977; DOI=10.1101/gad.12.2.163;
RA   Yeager T.R., DeVries S., Jarrard D.F., Kao C., Nakada S.Y., Moon T.D.,
RA   Bruskewitz R., Stadler W.M., Meisner L.F., Gilchrist K.W.,
RA   Newton M.A., Waldman F.M., Reznikoff C.A.;
RT   "Overcoming cellular senescence in human cancer pathogenesis.";
RL   Genes Dev. 12:163-174(1998).
//
RX   PubMed=10919661;
RA   Sarkar S., Julicher K.P., Burger M.S., Della Valle V., Larsen C.-J.,
RA   Yeager T.R., Grossman T.B., Nickells R.W., Protzel C., Jarrard D.F.,
RA   Reznikoff C.A.;
RT   "Different combinations of genetic/epigenetic alterations inactivate
RT   the p53 and pRb pathways in invasive human bladder cancers.";
RL   Cancer Res. 60:3862-3871(2000).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=24367658; DOI=10.1371/journal.pone.0084411;
RA   Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H.,
RA   Knowles M.A.;
RT   "Identification of mutations in distinct regions of p85 alpha in
RT   urothelial cancer.";
RL   PLoS ONE 8:E84411-E84411(2013).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//